Biotech Advances for Disease Management

USD 250.00

* Required Fields

USD 250.00

PAY BY INVOICE

Be the first to review this product

This edition of the Genetic Technology TOE depicts life sciences trends across disease management. Role of oncolytic viruses and gut microbiome in cancer immunotherapy is profiled in the TOE. Also profiled are a recent partnership among pharmaceutical companies, US FDA Breakthrough Therapy Designation received by a drug used for cytomegalovirus (CMV) treatment in transplant patients.The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered includin

Table of Contents

Biotech Advances for Disease ManagementRecent Biotech Innovations for Disease ManagementLeveraging Oncolytic Viruses for Enhancing Cancer ImmunotherapyEmerging Role of Gut Microbiome in Cancer ImmunotherapyTakeda Intends to Acquire TiGenix in a $632 Million Transaction Maribavir Receives US FDA Breakthrough Therapy Designation Clinical Trial Analysis and Industry InteractionsSummary of Clinical Studies for Cx601Industry Interactions




Related Research

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.